TransMedics Group, a medical tech company specializing in organ transplant therapy, granted 18,762 stock options and 12,414 restricted stock units to 9 new employees on July 29, 2026. These grants serve as inducements for employment and were approved by the company's Compensation Committee. The stock options have a $78 exercise price and vest over four years, encouraging employee retention. This move supports TransMedics' growth by attracting talent to advance its organ preservation technologies.
TransMedics reported a Q2 earnings beat mainly due to gains in low-margin logistics and pricing rather than increased organ transplants on its platform. Revenue growth was concentrated in liver transplants, which make up 78% of organ revenue, while h...
Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. This move could impact shareholders as it suggests possible mismanagement or misconduct at the company....
TransMedics Group reported a 21% increase in total revenue to $189.9 million for Q2 2026, driven by higher usage of its Organ Care System and logistics services. Despite a net income decline to $14.7 million due to increased operating expenses from s...
